C Malcontenti-Wilson
Overview
Explore the profile of C Malcontenti-Wilson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koh S, Ager E, Costa P, Malcontenti-Wilson C, Muralidharan V, Christophi C
Clin Exp Metastasis
. 2014 Jan;
31(4):395-405.
PMID: 24442969
Partial hepatectomy (PH), the preferred option for selected patients with colorectal cancer liver metastases (CRCLM), is associated with 40-80% tumor recurrence rates. Renin-angiotensin system (RAS) blockade inhibits tumor growth and...
2.
Nikfarjam M, Muralidharan V, Su K, Malcontenti-Wilson C, Christophi C
Int J Hyperthermia
. 2005 Jul;
21(4):319-32.
PMID: 16019858
The time course and extent of thermal ablative injury differs in liver compared to tumour tissue. This may be influenced by differences in the expression of heat shock proteins (HSP)...
3.
Nikfarjam M, Muralidharan V, Malcontenti-Wilson C, Christophi C
Eur J Surg Oncol
. 2003 Nov;
29(10):856-61.
PMID: 14624778
Aims: The failure of hepatic artery directed treatment of colorectal liver metastases may reflect a major portal venous contribution to tumour blood supply. This study provides ultrastructural details of the...
4.
Muralidharan V, Nikfarjam M, Malcontenti-Wilson C, Christophi C
J Clin Laser Med Surg
. 2003 May;
21(2):75-83.
PMID: 12737647
Background Data: Percutaneously applied interstitial laser hyperthermia (ILH) is a minimally invasive therapy that is currently used in the treatment of liver metastases. Despite its documented efficacy, theoretical considerations and...
5.
Muralidharan V, Malcontenti-Wilson C, Christophi C
J Clin Laser Med Surg
. 2002 Sep;
20(4):189-96.
PMID: 12206720
Objective: Our aim in this study was to investigate the characteristics of a diffuser-tipped optical fiber in producing tumor necrosis, compared to a standard bare-tipped fiber. The potential synergistic effect...
6.
Muralidharan V, Malcontenti-Wilson C, Christophi C
J Gastrointest Surg
. 2002 Jun;
5(6):646-57.
PMID: 12086904
Interstitial laser hyperthermia (ILH) is an in situ ablative technique used for the treatment of colorectal liver metastases. At present, few data exist concerning the optimum power settings required to...
7.
Muralidharan V, Malcontenti-Wilson C, Christophi C
J Surg Res
. 2002 Apr;
103(2):165-74.
PMID: 11922731
Background: Interstitial laser hyperthermia (ILH) is an in situ ablative technique for the treatment of colorectal liver metastases. A significant factor limiting tumor destruction is hepatic blood flow. Modulation of...
8.
Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, OBrien P
Clin Cancer Res
. 2001 Apr;
7(4):1052-60.
PMID: 11309357
Combretastatin A4P (CA4P) is a prodrug that, in active form, binds to tubulin microtubules of capillary endothelial cells. Studies to date indicate it has significant activity as a specific tumor...
9.
Brown W, Skinner S, Malcontenti-Wilson C, Vogiagis D, OBrien P
Gut
. 2001 Apr;
48(5):660-6.
PMID: 11302965
Background: Standard non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of colorectal cancer by 40-60% but the mechanism by which this occurs is uncertain. Selective cyclooxygenase 2 inhibitors are potentially ideal...
10.
Brown W, Skinner S, Malcontenti-Wilson C, Misajon A, DeJong T, Vogiagis D, et al.
J Gastroenterol Hepatol
. 2001 Feb;
15(12):1386-92.
PMID: 11197048
Background: Standard non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of colorectal cancer; however, their use as preventive agents is limited by their inherent toxicity. Drugs that selectively inhibit cyclooxygenase-2 (COX-2)...